We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Varespladib Infusion in Subjects With Sickle Cell Disease. (IMPACTS-2)

This study has been terminated.
(change in company plans)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01522196
First Posted: January 31, 2012
Last Update Posted: March 4, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Anthera Pharmaceuticals
  Purpose
The purpose of this study is to determine the effectiveness of A 001 infusion in preventing acute chest syndrome in sickle cell disease (SCD) subjects with vaso-occlusive crisis, fever, and elevated serum C-reactive protein (CRP).

Condition Intervention Phase
Sickle Cell Disease Vaso-occlusive Crisis Drug: Varespladib Other: Placebo (Normal Saline) Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: A Randomized, Double-blind, Placebo-Controlled Study With Varespladib Infusion (A-001) in Subjects With Sickle Cell Disease and Vaso-Occlusive Crisis for the Prevention of Acute Chest Syndrome At-Risk Subjects.

Resource links provided by NLM:


Further study details as provided by Anthera Pharmaceuticals:

Primary Outcome Measures:
  • Efficacy of A 001 infusion in preventing acute chest syndrome in sickle cell disease (SCD) subjects with the combination of vaso-occlusive crisis, fever, and elevated serum C-reactive protein (CRP). [ Time Frame: Various time points up to Day 30 ]

Secondary Outcome Measures:
  • Safety and tolerability of A 001 therapy when administered as a 48-hour continuous infusion to SCD subjects at-risk for acute chest syndrome. [ Time Frame: Various time points up to Day 30 ]
  • Impact of A-001 treatment on sPLA2 levels and CRP. [ Time Frame: Various time points up to Day 30 ]
  • Impact of A-001 treatment on the signs and symptoms of vaso-occlusive crisis. [ Time Frame: Various time points up to Day 30 ]
  • Impact of A-001 treatment on opioid use for pain in the treatment of vaso-occlusive crisis. [ Time Frame: Various time points up to Day 30 ]

Enrollment: 2
Study Start Date: February 2012
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Varespladib
48 hour continuous infusion delivered intravenously (IV)
Drug: Varespladib
48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
Placebo Comparator: Placebo
48 hour continuous infusion delivered intravenously (IV)
Other: Placebo (Normal Saline)
48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   5 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Genotypes Hb SS, Hb SC, sickle β°-thalassemia, sickle β+ -thalassemia
  • Pain consistent with vaso-occlusive crisis (clinical judgment) and not attributable to other causes
  • Serum CRP ≥5.0 mg/L at time of screening
  • Fever defined as oral temperature ≥38.0°C at time of screening
  • Age ≥5 years

Exclusion Criteria:

  • New or suspected new pulmonary infiltrate diagnosed by chest radiography
  • Females who are nursing, pregnant or intend to become pregnant
  • Renal dysfunction defined as a creatinine level >1.2 mg/dL for subjects aged 18 or less or a creatinine level >1.5 mg/dL for subjects over the age of 18
  • Hepatic dysfunction (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] >3 × upper limit of normal)
  • Acute neurologic dysfunction
  • Any medical condition for which transfusion may be needed imminently, and/or hemoglobin <5 g/dL
  • Red blood cell transfusion within 30 days prior to screening
  • Parenteral or oral corticosteroid therapy (inhaled steroids acceptable) within 7 days prior to screening
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01522196


Locations
United States, Georgia
Investigator Site 101
Atlanta, Georgia, United States, 30342
Sponsors and Collaborators
Anthera Pharmaceuticals
  More Information

Responsible Party: Anthera Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01522196     History of Changes
Other Study ID Numbers: AN-SCD1122
First Submitted: January 18, 2012
First Posted: January 31, 2012
Last Update Posted: March 4, 2014
Last Verified: January 2014

Keywords provided by Anthera Pharmaceuticals:
SCD

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn
Varespladib methyl
Phospholipase A2 Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action